LabCorp has signed a new, five-year agreement to license a blood test from Genfit designed to identify patients with risky cases of nonalcoholic steatohepatitis, also known as NASH.

Artificial intelligence-based drug molecule designer XtalPi has secured a mammoth series C funding round totaling $318.8 million, raised from global investment companies across the banking and technology sectors.

Dewpoint Therapeutics was founded because “the pharma industry has kind of been fighting with one arm behind its back,” the company’s CEO Amir Nashat said, citing his colleague Mark Murcko.

Cancer cells survive and proliferate with the help of nutrients and other materials that reach the cell nucleus via the “nuclear pore complex”—a door of sorts that’s vital for tumor survival. But what if that door could be blocked or, better yet, prevented from forming in the first place?

CapsoVision—maker of an ingestible camera pill for scanning the inside of a person’s gastrointestinal tract—has received word from the FDA that they may offer their device for fully remote, at-home use during the COVID-19 pandemic.

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed to go public with a $100 million Nasdaq IPO.

There’s a new type of line to wait in at the airport: United Airlines said it will begin providing COVID-19 screening tests for passengers on certain routes, allowing those who test negative to skip any quarantine requirements after they land.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.

It takes a vast network of at least 500,000 cells in six regions of the heart to keep the human body up and running. Now, there’s a new atlas of those cells, which cardiology researchers will be able to use to build their understanding of how a healthy heart operates—and what goes wrong when heart disease develops.

Poxel has shared the phase 3 data it hopes will secure approval for Type 2 diabetes drug imeglimin in Japan. The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combination with other drugs.